David Uffer and Caitilin Hamill join US consultancy Alira Health
Alira Health has in recent months added two senior experts to its team: Caitilin Hamill joined the firm as a Project Manager, bringing her extensive expertise in healthcare regulations to Alira Health’s clients worldwide, while David Uffer joined as a Partner, bringing his extensive expertise in business strategy, transaction services, and strategy execution.
David Uffer comes to Alira Health, formerly CMC Consulting Group (rebranded in December 2016), with over 20 years of management experience in medical device, products and clinical diagnostics. His broad expertise includes diverse segments such as respiratory and critical care medicine, urology/gynocology and breast health, minimally invasive surgery, oncology, interventional medicine, and in vitro and molecular diagnostics. He has led strategy development, strategic planning and business development activities in these fields for mid and large cap public companies.
Uffer has directed business development deals ranging from M&A, licensing, distribution and co-development for companies such as Medtronic (legacy Covidien), Hologic and Boston Scientific. He also held management roles at Integra Lifesciences and Abbott Labs.
“David is well-respected and accomplished in the healthcare space,” said Gabriele Brambilla, CEO of Alira Health. “He has led multi-billion dollar acquisitions and developed successful transformational strategies at his previous companies. He understands the internal operations and challenges of healthcare companies and will use his experience to help our clients assess risk, maximize value, and grow their businesses.”
Caitilin Hamill has over 15 years of experience in biotech R&D, clinical development of new therapeutic products and FDA regulation. Prior to joining Alira, she spent seven years as a reviewer and review management officer at the US Food and Drug Administration (FDA). She acted as a Chemistry, Manufacturing & Controls (CMC) reviewer in the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH).
As a Senior Review Management Officer within CBER’s Office of the Director, Hamill held responsibilities for center-level management of CBER’s review program. She has contributed to the development of more than 20 guidance documents and regulations and represented CBER and FDA on agency-level and international committees.
Commenting on her new role, Hamill said, “What most impresses me about Alira Health is the depth of expertise across all domains that are critical to successfully bring new medical products to patients: science, medicine, regulatory affairs, marketing, strategy and investment banking. Alira Health integrates its understanding of the entire business and product life cycle into every project. I am excited to contribute to Alira Health's holistic approach to innovation.”
Giacomo Basadonna, Managing Director of Global Medical Affairs at Alira Health, added, “With her scientific, regulatory, and business experience, Hamill will work across all areas of the firm contributing to our consulting, advisory and business development activities. She offers an exclusive combination of skills that are difficult to find in a single individual. Her curiosity and desire to link her rich and diverse learning experiences to Alira Health's existing environment makes her a great addition to our team.”
